|
1
|
Bussolino F, Mantovani A and Persico G:
Molecular mechanisms of blood vessel formation. Trends Biochem Sci.
22:251–256. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Folkman J: Seminars in Medicine of the
Beth Israel Hospital, Boston. Clinical applications of research on
angiogenesis. N Engl J Med. 333:1757–1763. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carmeliet P: Angiogenesis in health and
disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
André T, Chastre E, Kotelevets L, Vaillant
JC, Louvet C, Balosso J, Le Gall E, Prévot S and Gespach C: Tumoral
angiogenesis: Physiopathology, prognostic value and therapeutic
perspectives. Rev Med Interne. 19:904–913. 1998.(In French).
View Article : Google Scholar
|
|
6
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
|
|
8
|
Holmes K, Roberts OL, Thomas AM and Cross
MJ: Vascular endothelial growth factor receptor-2: Structure,
function, intracellular signalling and therapeutic inhibition. Cell
Signal. 19:2003–2012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrara N, Hillan KJ, Gerber HP and
Novotny W: Discovery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ivy SP, Wick JY and Kaufman BM: An
overview of small-molecule inhibitors of VEGFR signaling. Nat Rev
Clin Oncol. 6:569–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen HX and Cleck JN: Adverse effects of
anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol.
6:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Verheul HM and Pinedo HM: Possible
molecular mechanisms involved in the toxicity of angiogenesis
inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Höckel M and Vaupel P: Tumor hypoxia:
Definitions and current clinical, biologic, and molecular aspects.
J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Forsythe JA, Jiang BH, Iyer NV, Agani F,
Leung SW, Koos RD and Semenza GL: Activation of vascular
endothelial growth factor gene transcription by hypoxia-inducible
factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Semenza GL: HIF-1 and tumor progression:
Pathophysiology and therapeutics. Trends Mol Med. 8(Suppl):
S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harborne JB: Nature, distribution and
function of plant flavonoids. Prog Clin Biol Res. 213:15–24.
1986.PubMed/NCBI
|
|
18
|
Havsteen BH: The biochemistry and medical
significance of the flavonoids. Pharmacol Ther. 96:67–202. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai H, Hudson EA, Mann P, Verschoyle RD,
Greaves P, Manson MM, Steward WP and Gescher AJ: Growth-inhibitory
and cell cycle-arresting properties of the rice bran constituent
tricin in human-derived breast cancer cells in vitro and in nude
mice in vivo. Br J Cancer. 91:1364–1371. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hudson EA, Dinh PA, Kokubun T, Simmonds MS
and Gescher A: Characterization of potentially chemopreventive
phenols in extracts of brown rice that inhibit the growth of human
breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev.
9:1163–1170. 2000.PubMed/NCBI
|
|
21
|
Oyama T, Yasui Y, Sugie S, Koketsu M,
Watanabe K and Tanaka T: Dietary tricin suppresses
inflammation-related colon carcinogenesis in male Crj: CD-1 mice.
Cancer Prev Res (Phila). 2:1031–1038. 2009. View Article : Google Scholar
|
|
22
|
Ali MA, Choy H, Habib AA and Saha D:
SNS-032 prevents tumor cell-induced angiogenesis by inhibiting
vascular endothelial growth factor. Neoplasia. 9:370–381. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ushio-Fukai M: VEGF signaling through
NADPH oxidase-derived ROS. Antioxid Redox Signal. 9:731–739. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung HJ, Kim Y, Chang J, Kang SW, Kim JH
and Kwon HJ: Mitochondrial UQCRB regulates VEGFR2 signaling in
endothelial cells. J Mol Med (Berl). 91:1117–1128. 2013. View Article : Google Scholar
|
|
25
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
El-Kenawi AE and El-Remessy AB:
Angiogenesis inhibitors in cancer therapy: Mechanistic perspective
on classification and treatment rationales. Br J Pharmacol.
170:712–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J and Ibrahim RK: Tricin - a
potential multifunctional nutraceutical. Phytochem Rev. 9:413–424.
2010. View Article : Google Scholar
|
|
28
|
Shalini V, Pushpan CK, Sindhu G,
Jayalekshmi A and Helen A: Tricin, flavonoid from Njavara reduces
inflammatory responses in hPBMCs by modulating the p38MAPK and
PI3K/Akt pathways and prevents inflammation associated endothelial
dysfunction in HUVECs. Immunobiology. 221:137–144. 2016. View Article : Google Scholar
|
|
29
|
Shalini V, Jayalekshmi A and Helen A:
Mechanism of anti-inflammatory effect of tricin, a flavonoid
isolated from Njavara rice bran in LPS induced hPBMCs and
carrageenan induced rats. Mol Immunol. 66:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai H, Al-Fayez M, Tunstall RG, Platton S,
Greaves P, Steward WP and Gescher AJ: The rice bran constituent
tricin potently inhibits cyclooxygenase enzymes and interferes with
intestinal carcinogenesis in ApcMin mice. Mol Cancer Ther.
4:1287–1292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jeong YH, Chung SY, Han AR, Sung MK, Jang
DS, Lee J, Kwon Y, Lee HJ and Seo EK: P-glycoprotein inhibitory
activity of two phenolic compounds, (−)-syringaresinol and tricin
from Sasa borealis. Chem Biodivers. 4:12–16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cai H, Boocock DJ, Steward WP and Gescher
AJ: Tissue distribution in mice and metabolism in murine and human
liver of apigenin and tricin, flavones with putative cancer
chemopreventive properties. Cancer Chemother Pharmacol. 60:257–266.
2007. View Article : Google Scholar
|
|
33
|
Verschoyle RD, Greaves P, Cai H, Borkhardt
A, Broggini M, D’Incalci M, Riccio E, Doppalapudi R, Kapetanovic
IM, Steward WP, et al: Preliminary safety evaluation of the
putative cancer chemopreventive agent tricin, a naturally occurring
flavone. Cancer Chemother Pharmacol. 57:1–6. 2006. View Article : Google Scholar
|
